FATE at a glance
The past year
Chart+22.6% $1.28, close Nov 13
- From the highest close
- −59.0%
- Vs the 200-day average
- −35.8%
Short interest
History10.0M shares
- Of shares outstanding
- 8.20%
- Since the last report
- −6.1%
- Days to cover
- 8.3 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 9 – Nov 15
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
FATE price history
Loading recent earnings…
Investment thesis
What must happen next
Fate’s clonal iPSC master-cell approach can create value only if it proves that off-the-shelf, uniform cell products solve the logistical, cost, batch-variability, and access problems of patient-by-patient autologous cell therapy.HoldingMateriality: High
Item 1 states that autologous cell therapies are logistically complex, expensive, resource intensive, and hard to manufacture consistently at broad scale. If this holds, Fate owns a differentiated platform; if it fails, the company is just another cash-burning clinical biotech without product revenue.
Watch: Autologous CAR-T developers make turnaround time and manufacturing reliability good enough that the access advantage of off-the-shelf therapy narrows.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 states that autologous cell therapies are logistically complex, expensive, resource intensive, and hard to manufacture consistently at broad.
Open source ↗Fate’s integrated GMP facility and renewable clonal iPSC lines must turn platform science into repeatable, scalable manufacturing rather than one-off clinical batches.HoldingMateriality: High
Item 1 says Fate operates a 40,000+ square foot fully integrated GMP facility intended to support all phases of clinical development and initial commercialization. Manufacturing reliability is the bridge from promising biology to commercial economics; if it breaks, clinical success may still be uneconomic or unscalable.
Watch: Process changes, comparability failures, or batch-release problems prevent Fate from scaling iPSC-derived T cells or NK cells consistently.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 says Fate operates a 40,000+ square foot fully integrated GMP facility intended to support all phases of clinical.
Open source ↗Fate’s large iPSC intellectual-property estate and internal expertise must give it enough protection and development lead time for FT819 and follow-on candidates to matter before rivals copy or leapfrog the approach.HoldingMateriality: Medium
Item 1 says Fate’s proprietary iPSC platform is supported by over 600 issued patents and 550 pending patent applications. The platform needs defensibility; without it, even successful biology may be competed away before shareholders capture value.
Watch: Patent challenges, freedom-to-operate disputes, or licensing constraints weaken Fate’s control over core iPSC engineering and differentiation methods.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 says Fate’s proprietary iPSC platform is supported by over 600 issued patents and 550 pending patent applications.
Open source ↗Because Fate is clinical-stage and has minimal current revenue, management must keep burn low enough to reach clinical validation or partnering leverage without punitive financing.HoldingMateriality: Medium
GAAP annual operating cash flow improved from negative $248.2 million in FY2022 to negative $106.1 million in FY2025. The same platform upside can be valuable or worthless to current owners depending on how much dilution is required to reach proof of concept.
Watch: FT819 or other trials require larger, longer, or more complex studies before producing decision-grade data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow improved from negative $248.2 million in FY2022 to negative $106.1 million in FY2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Fate’s clonal iPSC master-cell approach can create value only if it proves that off-the-shelf, uniform cell products solve the logistical, cost, batch-variability, and access problems of patient-by-patient autologous cell therapy. If this holds, Fate owns a differentiated platform; if it fails, the company is just another cash-burning clinical biotech without product revenue.
Fate’s integrated GMP facility and renewable clonal iPSC lines must turn platform science into repeatable, scalable manufacturing rather than one-off clinical batches. Manufacturing reliability is the bridge from promising biology to commercial economics; if it breaks, clinical success may still be uneconomic or unscalable.
Fate’s large iPSC intellectual-property estate and internal expertise must give it enough protection and development lead time for FT819 and follow-on candidates to matter before rivals copy or leapfrog the approach. The platform needs defensibility; without it, even successful biology may be competed away before shareholders capture value.
Because Fate is clinical-stage and has minimal current revenue, management must keep burn low enough to reach clinical validation or partnering leverage without punitive financing. The same platform upside can be valuable or worthless to current owners depending on how much dilution is required to reach proof of concept.
All standing thesis claims
Original report summary
Fate is a high-risk platform option on whether clonal iPSC-derived, off-the-shelf cell therapies can replace bespoke autologous CAR-T economics in autoimmune disease and cancer before the balance sheet is consumed.
Bull case and bear case
Bull case and bear case for FATE Therapeutics
Where the evidence on FATE Therapeutics stands: Holding on the latest evidence (Nov 15, 2026). Of its 4 thesis points, 4 holding.
Bull case: what the evidence supports
Fate’s clonal iPSC master-cell approach can create value only if it proves that off-the-shelf, uniform cell products solve the logistical, cost, batch-variability, and access problems of patient-by-patient autologous cell therapy.
Fate’s integrated GMP facility and renewable clonal iPSC lines must turn platform science into repeatable, scalable manufacturing rather than one-off clinical batches.
Fate’s large iPSC intellectual-property estate and internal expertise must give it enough protection and development lead time for FT819 and follow-on candidates to matter before rivals copy or leapfrog the approach.
Because Fate is clinical-stage and has minimal current revenue, management must keep burn low enough to reach clinical validation or partnering leverage without punitive financing.
Bear case: what would count against it
Autologous CAR-T developers make turnaround time and manufacturing reliability good enough that the access advantage of off-the-shelf therapy narrows.
Process changes, comparability failures, or batch-release problems prevent Fate from scaling iPSC-derived T cells or NK cells consistently.
Patent challenges, freedom-to-operate disputes, or licensing constraints weaken Fate’s control over core iPSC engineering and differentiation methods.
Thesis-Break Engine
Thesis-break watch · FATE Therapeutics
No break has crossed FATE Therapeutics’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
FATE Therapeutics filed an SEC 8-K on 2026-11-05: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
FATE Therapeutics filed an SEC 8-K on 2026-11-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedOther material event.
FATE Therapeutics filed an SEC 8-K on 2026-09-28: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Autologous CAR-T developers make turnaround time and manufacturing reliability good enough that the access advantage of off-the-shelf therapy narrows.
- Process changes, comparability failures, or batch-release problems prevent Fate from scaling iPSC-derived T cells or NK cells consistently.
- Patent challenges, freedom-to-operate disputes, or licensing constraints weaken Fate’s control over core iPSC engineering and differentiation methods.
- FT819 or other trials require larger, longer, or more complex studies before producing decision-grade data.
FATE news
Loading headlines…
Financial statements
FATE income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
FATE: quick answers
- When does FATE Therapeutics (FATE) report earnings next?
- FATE Therapeutics's next results are projected for February 25, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 5, 2026. Earnings calendar
- What is FATE's short interest?
- As of October 30, 2026, 10.0M FATE shares were sold short, 8.20% of its shares outstanding, down 6.1% from the count before. At the stock's average daily volume that is 8.3 days to cover. FINRA publishes the count twice a month. FATE short interest history